1112 related articles for article (PubMed ID: 27006332)
41. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
42. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM
Eur J Cancer; 2022 Jul; 170():285-295. PubMed ID: 35643841
[TBL] [Abstract][Full Text] [Related]
43. Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
[TBL] [Abstract][Full Text] [Related]
44. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
Sanford M
Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
[TBL] [Abstract][Full Text] [Related]
45. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
[TBL] [Abstract][Full Text] [Related]
46. Enzalutamide in European and North American men participating in the AFFIRM trial.
Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
[TBL] [Abstract][Full Text] [Related]
47. Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK; van der Noort V; Hamberg P; Coenen JL; Aarts MJ; van Oort IM; van den Eertwegh AJ; Los M; van den Berg HP; Gelderblom H; Vrijaldenhoven S; Kerver ED; van Voorthuizen T; de Jong IJ; Haanen JB; Bergman AM;
Oncology; 2016; 91(5):267-273. PubMed ID: 27544669
[TBL] [Abstract][Full Text] [Related]
48. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
49. Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
[TBL] [Abstract][Full Text] [Related]
50. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
51. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
52. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Agarwal N; Nussenzveig R; Hahn AW; Hoffman JM; Morton K; Gupta S; Batten J; Thorley J; Hawks J; Santos VS; Nachaegari G; Wang X; Boucher K; Haaland B; Maughan BL
Clin Cancer Res; 2020 May; 26(9):2104-2110. PubMed ID: 31937614
[TBL] [Abstract][Full Text] [Related]
53. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
54. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
55. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
[TBL] [Abstract][Full Text] [Related]
56. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
57. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract][Full Text] [Related]
58. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN; Fizazi K; Saad F; Shore ND; De Giorgi U; Penson DF; Ferreira U; Efstathiou E; Madziarska K; Kolinsky MP; Cubero DIG; Noerby B; Zohren F; Lin X; Modelska K; Sugg J; Steinberg J; Hussain M;
N Engl J Med; 2020 Jun; 382(23):2197-2206. PubMed ID: 32469184
[TBL] [Abstract][Full Text] [Related]
59. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ
JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174
[TBL] [Abstract][Full Text] [Related]
60. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
